Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

re than 170 countries, including commercial, regulatory and medical affairs, and market access in key emerging markets.

The AbbVie Board also believes that, by leveraging AbbVie's established R&D infrastructure and expertise, the combination is well positioned to enhance innovation and end-to-end R&D capabilities, generating:

  • a best-in-class product development platform, with near-term new product launches in liver disease (HCV), neuroscience, immunology, oncology, rare diseases, ophthalmology, and renal; and
  • expertise and infrastructure, including regulatory, health economics and outcomes research, and market access to expand product indications to meet patient needs. AbbVie's track record of product optimisation is evidenced by its growth of the Humira® franchise through increased penetration in existing indications, geographic expansion, and approvals for new indications.
  • The AbbVie Board believes that the enhanced financial profile of New AbbVie would offer greater strategic and financial flexibility, enabling:

  • the opportunity to maximise Shire's rare disease and neuroscience franchises including resources to fully globalise Shire's planned launches;
  • the potential for strengthened sustainability of top-tier EPS growth, attractive free cash flow and enhanced return of capital policy; and
  • a world-class business development group to drive continued portfolio expansion and utilise M&A to supplement organic growth with access to cash and financial wherewithal not available on a standalone basis.
  • AbbVie believes that a potential re-rating of New AbbVie is possible due to continued strength in the Humira® franchise (the world's top selling medicine globally in 2013), the launch of a HCV therapy, advancement of exciting late-stage opportunities in oncology, immunology and other areas, and Shire's complementary rare disease and neuroscience platform.

    AbbVie anticipates m
    '/>"/>

    SOURCE AbbVie Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
    2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
    3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
    4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
    5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
    6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
    7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
    8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
    10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
    11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
    (Date:9/18/2014)... , Sept. 18, 2014 Research and ... Market Monitor : Global Chiral Separation Columns Market" ... chromatography is a technique involving two enantiomers of the ... consisting of a single enantiomer, thus possessing different elution ... such as cellulose. The chiral separation chromatography ...
    (Date:9/18/2014)... , Sept. 18, 2014  Decision Resources ... the United States , 54 ... GlaxoSmithKline,s BRAF inhibitor Tafinlar for BRAF -mutation-positive ... who have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among ... percentage (42 percent and 43 percent, respectively) expects ...
    Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2Micro Market Monitor: Global Chiral Separation Columns Market 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2
    ... The award recognizes outstanding journalism demonstrating the ... discoveries and scientific,breakthroughs., WASHINGTON, June 19 ... announces the winners of the 7th Annual,Michael ... in honor of FBR,s,Chairman and 2008 Congressional ...
    ... Kendle (Nasdaq: KNDL ), a,leading global full-service ... its experts will present at the upcoming Drug,Information ... scheduled,for June 22-26, 2008, at the Boston Convention ... speak on key topics in the clinical,development industry, ...
    Cached Medicine Technology:The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 3
    (Date:9/18/2014)... jacket is a hip- or waist-length garment for the ... in the front or slightly on the side. A ... a coat, which is outerwear. Some jackets are fashionable, ... well-known clothing manufacturer and retailer, has delightedly released its ... are offered at extremely low prices? , The ...
    (Date:9/18/2014)... Older people become more physically vulnerable during bereavement, new ... hormones during bereavement changes with age, British researchers say. ... more likely to have weakened immune systems and develop ... and months after loss, we can suffer from reduced ... white blood cell and as such are essential at ...
    (Date:9/18/2014)... Limited spots remain at Becker's Healthcare's upcoming ... are still available for Becker's ASC 21st Annual Meeting ... 23-25, 2014 at the Swissotel Chicago. , Only 10 ... Strategy Roundtable on November 4, 2014 at the Ritz ... Hospital Review Chief Executive Officer Strategy Roundtable on November ...
    (Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
    (Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... can quickly alter the way brain cells communicate with one ... Sept. 18 in Current Biology , are a step ... Experts said the hope is to eventually be able to ... a drug -- and which people would fare better with ...
    Breaking Medicine News(10 mins):Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
    ... States Senate Committee on Small Business and Entrepreneurship ... J. Snowe, R-Maine, today convened a roundtable to ... small businesses. Participants at the roundtable, entitled "Healthcare ... of Small Businesses," included U.S. Sen. Ron Wyden, ...
    ... -- Skyrocketing prescription drug prices are stinging Illinoisans over the ... the basics, like food and utilities, in order to afford needed ... drugs see record price increases, the majority of the state,s 50 ... medications in the coming year. , , "No ...
    ... "Keratosis Pilaris," "Keratosis Pilaris." Hmm, sounds weird, doesn,t it? ... to the American Academy of Dermatology nags 40 percent of ... family of moisturizers is launching www.littleredbumps.com , ... associated with Keratosis Pilaris also known as KP. , ...
    ... OAKLAND, Calif., July 9 Members of SEIU UHW ... outside the Oakland Federal Building, 1301 Clay Street, to release newly ... former top union officials were advised by their attorney that some ... and then followed their lawyer,s advice on how to cover them ...
    ... can cause menstrual woes, infertility, researchers note , THURSDAY, ... bring some relief to the one in 10 women ... disease called polycystic ovarian syndrome (PCOS). , ... hormones -- including testosterone -- and often develop ovarian ...
    ... chest pain patients in the emergency department, instead of the ... length of stay and hospital charges, according to a study ... WA. The SOC workup, which is timely and expensive, consists ... stress testing. , , Fifty patients were included in ...
    Cached Medicine News:Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3Health News:High Rx Costs Hammering Illinois' 50+ Population 2Health News:Video: What Are Those Little Red Bumps? 2Health News:Video: What Are Those Little Red Bumps? 3Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Acupuncture, Exercise May Ease Polycystic Ovarian Syndrome 2
    ... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
    ... cover the range from 2ul to 5000ul. ... lock design prevents inadvertent volume change. Novel ... Whole pipette is autoclavable at 121C(250F). To ... Suitable for one-handed operation. Auto or ...
    ... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
    ... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
    Medicine Products: